National Health Investors (NHI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Achieved a return to growth in 2024, with increases in Nareit FFO, Normalized FFO, and Funds Available for Distribution, surpassing initial expectations.
Total Shareholder Return (TSR) for 2024 was 30.6%, outperforming the Nareit Healthcare REIT Index and continuing multi-year outperformance.
Portfolio optimization led to $11 million in deferral repayments and a 32% increase in Senior Housing Operating Portfolio NOI.
Over $235 million invested at an average yield of 8.6%, with leverage improved to a net debt-to-adjusted EBITDA of 4.1x.
Raised $262 million in equity, with $119 million remaining available; closed a $67.5 million acquisition in January and have $106 million under LOI.
Voting matters and shareholder proposals
Proposal 1: Election of four directors for one-year terms if Proposal 2 passes, or two/three-year terms if not.
Proposal 2: Amendment to declassify the Board, moving to annual director elections by 2027.
Proposal 3: Advisory vote on executive compensation (say-on-pay).
Proposal 4: Ratification of BDO USA, P.C. as independent auditor for 2025.
Proposal 5: Stockholder proposal from Land & Buildings (L&B) to declassify the Board, which the Board recommends voting against in favor of Proposal 2.
L&B is nominating two dissident directors; the Board recommends voting for its own four nominees.
Board of directors and corporate governance
Board expanded from four to eight members since 2020, with female representation rising to 37.5% and average tenure dropping to seven years.
Recent retirements of two founding members; five new independent directors added in five years.
Special Committee of Non-Interested Directors established to oversee NHC lease negotiations.
Board leadership separated between Chair (McCabe) and CEO (Mendelsohn); six of eight directors are independent.
Enhanced governance guidelines, including strengthened director qualification standards and stock ownership requirements.
Latest events from National Health Investors
- Normalized FFO per share rose 8.9% in Q4, with SHOP NOI up 125% and 2026 outlook strong.NHI
Q4 202527 Feb 2026 - Q2 FFO, FAD, and revenues rose, but net income fell; SHOP occupancy and guidance increased.NHI
Q2 20242 Feb 2026 - SHOP occupancy and NOI surged, but net income and FFO per share declined; liquidity remains strong.NHI
Q3 202416 Jan 2026 - Q4 and 2024 outperformed, with strong growth and 2025 guidance signaling further gains.NHI
Q4 20246 Jan 2026 - Proxy contest aims to overhaul board independence and governance, urging immediate declassification.NHI
Proxy Filing1 Dec 2025 - Board refreshment, strong financials, and governance reforms drive growth and shareholder value.NHI
Proxy Filing1 Dec 2025 - Board refreshment, strong returns, and governance enhancements drive long-term growth.NHI
Proxy Filing1 Dec 2025 - Proxy contest targets board independence, conflicts, and supports declassifying the board.NHI
Proxy Filing1 Dec 2025 - Board expanded with Robert W. Chapin, Jr.'s appointment; proxy details forthcoming.NHI
Proxy Filing1 Dec 2025